Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Details
Publication Year 2023,Volume 7,Issue #19,Page 5898-5903
Journal Title
Blood Advances
Publication Type
Review
Abstract
Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell markers, including B-cell maturation antigen (BCMA), FcRH5, and G protein-coupled receptor GPRC5D. These bispecific antibodies so effectively deplete plasma cells (and to some extent T-cells) that patients are at increased risk of developing infections. A systematic review and meta-analysis of infections in published studies of patients with myeloma treated with bispecific antibodies was conducted to better characterize the infection risks. A literature search used MEDLINE, EMBASE, and Cochrane to identify relevant studies between inception and February 10, 2023, including major conference presentations. Phase 1b-3 clinical trials and observational studies were included. Sixteen clinical trials comprising 1666 patients were included. Median follow-up was 7.6 months and 38% of the cohort had penta-drug refractory disease. Pooled prevalence of all-grade infections was 56%, whereas the prevalence of grade >/=3 infections was 24%. Patients who were treated with BCMA-targeted bispecifics had significantly higher rates of grade >/=3 infections than non-BCMA bispecifics (25% vs 20%). Similarly, patients treated with bispecifics in combination with other agents had significantly higher rate of all-grade infection than those receiving monotherapy (71% vs 52%). In observational studies (n = 293), excluded from the primary analysis to ensure no overlap with patients in clinical trials, several infections classically associated with T-cell depletion were identified. This systematic review identifies BCMA-targeted bispecifics and bispecific combination therapy as having higher infection risk, requiring vigilant infection screening and prophylaxis strategies.
Publisher
American Society of Hematology
Keywords
Humans; *Multiple Myeloma/drug therapy/pathology; *Antibodies, Bispecific/adverse effects; B-Cell Maturation Antigen/therapeutic use; Immunotherapy; T-Lymphocytes; CD3 Complex
Department(s)
Infectious Diseases; Clinical Haematology
PubMed ID
37467036
Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2023010539
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-12-05 12:49:38
Last Modified: 2023-12-05 12:50:18

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙